Загрузка...
Measuring differential treatment benefit across marker specific subgroups: the choice of outcome scale
Clinical and epidemiological studies of anticancer therapies increasingly seek to identify predictive biomarkers to obtain insights into variation in treatment benefit. For time to event endpoints, a predictive biomarker is typically assessed using the interaction between the biomarker and treatment...
Сохранить в:
| Опубликовано в: : | Contemp Clin Trials |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5568905/ https://ncbi.nlm.nih.gov/pubmed/28254404 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cct.2017.02.007 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|